ABSTRACT
Osteomyelitis encompasses various skeletal disorders that can cause significant morbidity to patients. Currently, osteomyelitis caused by bacterial microorganisms requires long treatment with limited specificity, leading to recurrence, and a need for extensive surgical debridement in patients. Thus, there is a critical need to develop alternative and more effective therapeutic strategies to overcome moderate therapeutic efficacy. Here, we discuss the feasibility of nanotechnology-based approaches for the management of osteomyelitis. Nanostructured drug delivery systems have high drug loading with minimal side effects and can be translated for the management of infected wounds. In Chapter 11, we review the nanoformulations under development and their potential for clinical translation.
